{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:23:07Z","timestamp":1787163787331,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.clml.2016.08.010","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T14:34:14Z","timestamp":1470926054000},"page":"644-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Myelomatous Involvement of the Central Nervous System"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-8637","authenticated-orcid":false,"given":"Utkarsh","family":"Painuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Mauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.08.010_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.08.010_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2016.08.010_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03401.x","article-title":"Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations","volume":"117","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central nervous system myelomatosis: review of the literature","volume":"80","author":"Nieuwenhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.010_bib7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.010_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/hon.1021","article-title":"Emergence of central nervous myeloma in the era of novel agents","volume":"30","author":"Gangatharan","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2016.08.010_bib9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2016.08.010_bib10","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/sj.leu.2404712","article-title":"Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders","volume":"21","author":"Morice","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.010_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2016.08.010_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3","article-title":"Cerebral and meningeal multiple myeloma after autologous stem cell transplantation: a case report and review of the literature","volume":"62","author":"Petersen","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.08.010_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archinte.1980.00330140114029","article-title":"Meningeal myelomatosis","volume":"140","author":"Spiers","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2016.08.010_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2013.11.004","article-title":"Patterns of central nervous system involvement in relapsed and refractory multiple myeloma","volume":"14","author":"Abdallah","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2016.08.010_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.08.010_bib16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2016.08.010_bib17","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/s12032-010-9527-y","article-title":"Mechanism of action of immunomodulatory agents in multiple myeloma","volume":"27","author":"Reske","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2016.08.010_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-007-0424-9","article-title":"Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib","volume":"60","author":"Hemeryck","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2016.08.010_bib19","doi-asserted-by":"crossref","first-page":"e71754","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.08.010_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2005.00591.x","article-title":"Thalidomide for the treatment of leptomeningeal multiple myeloma","volume":"76","author":"Yutaka","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871524914999140818111514","article-title":"Novel agents in CNS myeloma treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"10.1016\/j.clml.2016.08.010_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1034\/j.1600-0609.2003.00022.x","article-title":"Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?","volume":"70","author":"Vicari","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3109\/10428194.2012.718343","article-title":"Effective treatment of pomalidomide in central nervous system myelomatosis","volume":"54","author":"Mussetti","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.010_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2016.08.010_bib25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2016.08.010_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ejh.12247","article-title":"Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement","volume":"92","author":"Nahi","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.08.010_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11060-011-0788-x","article-title":"Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report","volume":"107","author":"Renfrow","year":"2012","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clml.2016.08.010_bib28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-011-0612-7","article-title":"Salvage therapy with single agent bendamustine for recurrent glioblastoma","volume":"105","author":"Chamberlain","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clml.2016.08.010_bib29","first-page":"1571","article-title":"Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system","volume":"47","author":"Greig","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2016.08.010_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF00255766","article-title":"Pharmacokinetics of melphalan in children following high-dose intravenous injection","volume":"10","author":"Taha","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2016.08.010_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/oxfordjournals.aje.a009786","article-title":"Factors influencing the optimal control-to-case ratio in matched case-control studies","volume":"149","author":"Hennessy","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2016.08.010_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.bmt.1704777","article-title":"Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion","volume":"35","author":"Quach","year":"2005","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2016.08.010_bib33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","article-title":"Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience","volume":"94","author":"Katodritou","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.08.010_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.12404","article-title":"Central nervous system multiple myeloma\u2014potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains","volume":"162","author":"Lee","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:56Z","timestamp":1761870476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016303846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S2152265016303846"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelomatous Involvement of the Central Nervous System","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}